PO-0740: Nodal clearance rate and efficacy of individualised SN-based pelvic IMRT for prostate cancer  by Müller, A. et al.
S346                                                                                                                                                    ESTRO 35 2016 
______________________________________________________________________________________________________ 
group (p =0.056), and the 5-year actuarial grade 2+ GI 
toxicity rate was lower in the IMRT group than in the 3D-CRT 
group (5.0% vs. 12.1%, p <0.01). A lower incidence of acute 
genitourinary (GU) grade 2+ toxicities occurred in the IMRT 
group than in the 3D-CRT group (7.1% vs. 16.4%, p = 0.001). 
The 5-year actuarial grade 2+ GU toxicity rate for the IMRT 
vs. the 3D-CRT group was 16.3% vs. 21.7% (p = 0.103), 
respectively. 
 
Conclusion: IMRT combined with I-125 brachytherapy in 
prostate cancer patients found a lower incidence of toxicities 
than 3D-CRT combination, without compromise of 
biochemical outcomes.  
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Purpose or Objective: Studies on extended or sentinel node 
(SN) pelvic lymph node dissection (PLND) have shown a higher 
detection rate compared to standard PLND in high risk 
prostate cancer (HRPC). In accordance with these findings, 
we previously demonstrated that ~30% of SNs in HRPC-
patients were detected outside of the radiotherapy volume 
for elective lymph node irradiation. The aim of this study was 
to assess efficacy of individually SN-guided pelvic intensity 
modulated radiotherapy (IMRT) by determining nodal 
clearance rate {(n expected nodal involvement – n observed 
regional recurrences)/ n expected nodal involvement} in 
comparison to surgically staged patients. 
 
Material and Methods: Data on 475 HRPC patients were 
examined. Sixty-one consecutive patients received pelvic SN-
based IMRT (5x1.8Gy/week to 50.4Gy (pelvic 
nodes+individual SN) and an integrated boost with 
5x2.0Gy/week to 70.0Gy to prostate + (base of) seminal 
vesicles) and neo-/adjuvant long-term androgen deprivation 
therapy; 414 patients after SN-PLND were used to calculate 
the expected nodal involvement rate for the radiotherapy 
sample. Biochemical control and overall survival (OS) were 
estimated for the SN-IMRT patients using the Kaplan-Meier 
method. The expected frequency of nodal involvement in the 
radiotherapy group was estimated by imputing frequencies of 
node-positive patients in the surgical sample to the pattern 
of Gleason, PSA, and T-category in the radiotherapy sample. 
 
Results: After a median follow-up of 61 months, five year OS 
after SN-guided IMRT reached 84.4%. Biochemical control 
according to the Phoenix definition was 73.8%. The nodal 
clearance rate of SN-IMRT reached 94%. The estimated nodal 
involvement in the SN-IMRT group was 28.6% (95%-CI:19.3%-
37.7%). Retrospective follow-up evaluation is the main 
limitation. 
 
Conclusion: Radiation treatment of pelvic nodes 
individualized by inclusion of SN is an effective regional 
treatment modality in HRPC patients. The pattern of relapse 
indicates that the SN-based target volume concept correctly 
covers individual pelvic nodes. Thus, this SN-based approach 
justifies further evaluation including current dose-escalation 
strategies to the prostate in a larger prospective series. 
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Purpose or Objective: Whether the benefit of androgen 
ablation therapy (AAT) remains currently unclear in the era 
of dose escalation and the recent radiation therapy oncology 
group trials regarding this issue are still under accrual. We 
tried to evaluate the role of long-term adjuvant AAT for more 
than 12 months after completion of high-dose intensity 
modulated radiotherapy (IMRT) for high-risk prostate cancer 
patients at the single institution retrospectively.  
 
Material and Methods: Between 2005 and 2013, there were 
177 high-risk patients treated with radical IMRT. From 2005 
to 2009, 25 patients were treated by LINAC-IMRT, and since 
2010, remaining 152 patients were treated by helical 
tomotherapy. High-risk was defined as having one or more 
among three factors such as pretreatment prostate specific 
antigen (pPSA) levels > 20 ng/ml, or Gleason score (GS) > 7, 
or clinical stage ≥ T3a. Ninety-four patients (53.1%) had pPSA 
levels > 20 ng/ml, and 91 patients (51.4%) had GS > 7. 
Clinical stage T3 or 4 was diagnosed in 143 patients (80.8%) 
and 21 (11.9%) had pelvic lymph node metastasis initially. 
Among all patients, 95.5% received neoadjuvant/concurrent 
and 91.1% had adjuvant AAT. Median fraction size was 2.2 Gy 
for prostate plus proximal seminal vesicles with 
simultaneously integrated boost during whole pelvic 
irradiation of 1.8 Gy fraction. Most patients (88.1%) received 
whole pelvic irradiation of a median of 45.0 Gy. Median total 
nominal dose was 72.6 Gy (66.0 ~ 78.0) which was equivalent 
to a median of 81.4 Gy α/β 1.5 (74.2 ~ 86.3) in biologically 
effective dose of 1.8 Gy fraction. Biochemical failure (BCF) 
was defined as nadir plus 2 ng/ml.  
 
Results: Follow-up period was ranged from 6 to 117 months 
(median: 37). Eighteen patients (10.2%) developed BCF and 5-
year BCF-free survival rate (BCFFS) was 83.1%. Six out of 18 
BCF patients eventually developed clinical failure and 5-year 
clinical failure-free survival (CFFS) was 93.7%. 5-year cause-
specific survival (CSS) and overall survival (OS) was 99.1% and 
95.8%, respectively. Several potential prognostic factors were 
analyzed for each survival endpoints by multivariate analysis. 
Whether adjuvant AAT or not (p=0.000) and N stage (p=0.016) 
were significant factors affecting BCFFS but no factors were 
significant for CFFS, CSS, or OS. Biologically effective dose 
according to 1.8 Gy (≤80.0 Gy α/β 1.5 vs. > 80.0 Gyα/β 1.5) 
was not a significant factor in all survival endpoints. There 
was only one patient who suffered urethral stricture of grade 
3 late toxicity. No patient suffered grade 3+ in 
gastrointestinal or grade 4+ in genitourinary late toxicity. s 2 
ng/ml.  
 
Conclusion: Based on BCF end point, even high-dose IMRT 
was an insufficient treatment for high-risk prostate cancer 
patients if adjuvant AAT was not added. The addition of 
adjuvant AAT significantly reduced the BCF, although longer 
follow-up is needed to determine if the combined treatment 
impacts significantly on other survivals 
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